TOKYO--(BUSINESS WIRE)--Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin)(TOKYO:4151) today announced revised forecasts for the interim and full year period of the fiscal year ending March 31, 2009. While the consolidated full year net sales forecast is unchanged, operating income for the full year is expected to be 12.3% lower than previously forecast, mainly due to lower than expected sales of certain pharmaceutical products and the worldwide slowdown in economic growth. Full year net income is expected to be 39.3% lower than previously forecast, largely as a result of one-time tax expenses related to the planned disposal of a subsidiary and expenses related to the integration with Kirin Pharma.
